Orforglipron: The GLP-1 Pill Without Injections

Table of Contents

1. What Makes Orforglipron Different
2. The Approval and What the Label Says
3. How the Body Handles the Pill
4. The Weight-Loss Trials
5. The Diabetes Trials
6. Compared With Injected Semaglutide and Tirzepatide
7. Keeping the Weight Off: Switching and Stopping
8. Side Effects in the Trials and on the Label
9. The Thyroid C-Cell Tumour Warning
10. Drug Interactions, Contraception and Pregnancy
11. Heart and Liver Findings So Far
12. What Is Not Yet Known
13. Key Research Papers
14. Connections
15. Featured Videos

What Makes Orforglipron Different

Glucagon-like peptide-1 (GLP-1) is a gut hormone released after a meal. It tells the pancreas to release insulin when blood sugar is high, slows the emptying of the stomach and quiets appetite in the brain. Semaglutide, tirzepatide, liraglutide and dulaglutide all copy this hormone as modified peptides. Peptides break down in the stomach, which is why most of them are injected under the skin.

The one older pill in the class, oral semaglutide, solves the digestion problem with an absorption enhancer and strict timing. Its label tells people to take it on an empty stomach in the morning with no more than 4 ounces of plain water, and then to wait at least 30 minutes before eating, drinking anything else or taking other oral medicines.

Orforglipron is not a peptide at all. It is a non-peptide small molecule that switches on the human glucagon-like peptide-1 receptor directly. Its label reads simply: take it by mouth once a day, with or without food, swallowed whole, not broken, crushed or chewed, and no more than one tablet a day. The phase 2 diabetes trial gave it "with no food or water restrictions." In a food-effect study described on the label, a meal lowered total exposure by 19%, which the label calls not clinically relevant.

One unusual detail follows from the chemistry. The label states that orforglipron is not pharmacologically active in rats, mice or rabbits — it has no effect on the receptor in those animals. That matters for the thyroid warning further down.

The Approval and What the Label Says

The U.S. Food and Drug Administration's Drugs@FDA database lists the original new drug application as a new molecular entity, approved on 1 April 2026, with a labelling supplement approved on 4 August 2026. The label read for this page carries an effective date of 29 July 2026.

• Indication. Together with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep the weight off long term in adults with obesity, or adults with overweight plus at least one weight-related condition. The label approved so far is for weight management; the diabetes trials below were not the basis of the approved indication.
• Limit of use. The label does not recommend combining it with another glucagon-like peptide-1 receptor agonist.
• Dose schedule as the label gives it. Start at 0.8 mg once daily. After at least 30 days, 2.5 mg. After at least 30 more days, 5.5 mg. From there the dose may go up, one step at a time and at least 30 days apart, to 9 mg, 14.5 mg and 17.2 mg, depending on response and tolerability. The maximum is 17.2 mg once daily. The label explains the slow climb as a way to lower the risk of stomach and bowel reactions.
• Missed doses. The label says to take a missed dose as soon as possible without doubling the next one, and to restart at a lower step if 7 or more doses in a row are missed.
• Boxed warning. Risk of thyroid C-cell tumours (see below).
• Contraindications. A personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or a known serious allergic reaction to orforglipron or the tablet's ingredients.
• Major warnings. Acute pancreatitis; severe stomach and bowel reactions (the label advises against its use in severe gastroparesis); acute kidney injury from dehydration; low blood sugar when combined with insulin or a sulfonylurea; serious allergic reactions; worsening of diabetic eye disease in type 2 diabetes; acute gallbladder disease; and inhaling stomach contents during general anaesthesia or deep sedation, because the drug slows stomach emptying.

Why the label's doses differ from the trial doses. The trials used an investigational formulation dosed at 6, 12 and 36 mg. The label converts these to "equivalent dosages" of the marketed tablet: 5.5, 9 and 17.2 mg. The cardiovascular trial states directly that a 36 mg capsule equals a 17.2 mg tablet. Doses quoted from published trials on this page are the trial doses.

How the Body Handles the Pill

In a small study of 10 healthy adults, about 79% of an oral dose reached the bloodstream (absolute bioavailability 79.1%); the label gives 77%. Orforglipron is broken down mainly by the liver enzyme cytochrome P450 3A4, and 87% of a dose leaves the body in the stool, with less than 1% in urine.

According to the label, blood levels peak 4 to 8 hours after a dose, the elimination half-life is about 29 to 49 hours, and a steady level is reached after about a week of daily dosing. Kidney impairment, including severe impairment and kidney failure, did not change blood levels. Liver impairment did: exposure rose 1.7-fold in moderate and 4.6-fold in severe liver impairment. Stomach-acid reducers had no effect.

The Weight-Loss Trials

Phase 2 (36 weeks, 272 adults without diabetes)

Adults with obesity, or overweight plus a weight-related condition, took 12, 24, 36 or 45 mg daily or placebo. At 26 weeks weight fell 8.6% to 12.6% on orforglipron against 2.0% on placebo; at 36 weeks, 9.4% to 14.7% against 2.3%. Between 46% and 75% lost at least 10% of their weight, against 9% on placebo. Stomach and bowel side effects, mostly mild to moderate and mostly during dose escalation, led 10% to 17% of people to stop the drug — a higher dropout than in the phase 3 trials below.

ATTAIN-1 (72 weeks, 3,127 adults without diabetes)

The phase 3 trial behind the approval. Average weight change was −7.5% on 6 mg, −8.4% on 12 mg and −11.2% on 36 mg, against −2.1% on placebo. On 36 mg, 54.6% lost at least 10%, 36.0% at least 15% and 18.4% at least 20%; on placebo the figures were 12.9%, 5.9% and 2.8%. Waist size, systolic blood pressure, triglycerides and non-HDL cholesterol all improved. Read the other way: on the top dose about 45% did not reach a 10% loss, and side effects ended treatment for 5.3% to 10.3% on orforglipron against 2.7% on placebo. The label adds that 22% to 24% of people on the drug and 30% on placebo stopped the trial drug for any reason, and that the week-72 weight was missing for 14% to 24% of each group.

ATTAIN-2 (72 weeks, 1,613 adults with type 2 diabetes)

Weight loss was smaller than in ATTAIN-1. Weight fell 5.1%, 7.0% and 9.6% on 6, 12 and 36 mg against 2.5% on placebo, and hemoglobin A1c, the three-month blood-sugar average, also improved. Side-effect discontinuations were 6.1% to 9.9% against 4.1%. Ten people died during the trial, six on orforglipron and four on placebo; investigators judged no orforglipron death to be caused by the drug.

ATTAIN-J (72 weeks, 238 Japanese adults)

In Japanese adults with obesity-related disease, weight fell 5.9%, 8.7% and 7.9% on 6, 12 and 36 mg against 0.6% on placebo — here the highest dose did not beat the middle one. Nausea led 8% of the 36 mg group to stop treatment.

The Diabetes Trials

Orforglipron was also tested as a diabetes drug in the ACHIEVE programme. These results are real, but on the label read for this page they are not part of the approved use.

• Phase 2 (26 weeks, 383 adults). Hemoglobin A1c fell by up to 2.10 points on orforglipron, against 0.43 on placebo and 1.10 on the weekly injection dulaglutide. Weight fell by up to 10.1 kg, against 2.2 kg on placebo and 3.9 kg on dulaglutide. Stomach and bowel events affected 44.1% to 70.4% on orforglipron, 18.2% on placebo and 34.0% on dulaglutide.
• ACHIEVE-1 (40 weeks, 559 adults with early diabetes on diet and exercise alone). Starting from an average hemoglobin A1c of 8.0%, it fell 1.24, 1.47 and 1.48 points on 3, 12 and 36 mg, against 0.41 on placebo, ending at 6.5% to 6.7%. Weight fell 4.5% to 7.6% against 1.7%. No severe low-blood-sugar episodes occurred. Side effects ended treatment for 4.4% to 7.8%, against 1.4% on placebo.
• ACHIEVE-2 (40 weeks, 962 adults on metformin), against dapagliflozin. Hemoglobin A1c fell 1.23 to 1.56 points on orforglipron and 0.81 on the sodium-glucose cotransporter 2 inhibitor dapagliflozin. Stomach and bowel events affected 46% to 54% on orforglipron against 12% on dapagliflozin, and 15% to 20% stopped the study drug, against 6%.
• ACHIEVE-3 (52 weeks, 1,698 adults on metformin), against oral semaglutide. The only head-to-head trial against another drug of the same class. Hemoglobin A1c fell 1.71 and 1.91 points on 12 and 36 mg orforglipron, and 1.23 and 1.47 on 7 and 14 mg oral semaglutide; both orforglipron doses were superior to both semaglutide doses. The other side: stomach and bowel events affected 58% to 59% on orforglipron against 37% to 45% on semaglutide, side-effect discontinuations were 9% to 10% against 4% to 5%, and pulse rose 3.7 to 4.7 beats per minute against 1.0 to 1.5.
• ACHIEVE-5 (40 weeks, 546 adults on insulin glargine). Added to insulin, hemoglobin A1c fell 1.58 to 1.88 points against 0.79 on placebo, weight fell 2.6% to 5.4% against a 0.2% gain, and clinically significant low blood sugar did not increase.
• ACHIEVE-J (52 weeks, 401 Japanese adults, open-label safety trial). 85% had at least one adverse event, mostly mild. Side effects ended treatment for 5% on 3 mg, 8% on 12 mg and 14% on 36 mg. No severe low-blood-sugar events occurred.

Compared With Injected Semaglutide and Tirzepatide

No published trial has put orforglipron head to head with injected semaglutide or tirzepatide for weight loss. The list below sets three separate placebo-controlled trials in adults without diabetes side by side. That is a cross-trial comparison: the people, years, diets, dropout rates and methods differ, so the gaps are a rough guide, not a measured difference.

• ATTAIN-1 — orforglipron 36 mg daily pill, 72 weeks: weight −11.2% on the drug, −2.1% on placebo.
• STEP 1 — semaglutide 2.4 mg weekly injection, 68 weeks: weight −14.9% on the drug, −2.4% on placebo.
• SURMOUNT-1 — tirzepatide 15 mg weekly injection, 72 weeks: weight −20.9% on the drug, −3.1% on placebo.

Dropouts also line up differently. Side effects ended treatment for 5.3% to 10.3% on orforglipron in ATTAIN-1 and for 4.3% to 7.1% on tirzepatide in SURMOUNT-1. STEP 1 reported only stomach-and-bowel discontinuations, 4.5% on semaglutide against 0.8% on placebo, so its figure is not the same measure.

A 2026 network meta-analysis in the BMJ, pooling 262 trials of 19 obesity drugs, put the one-year weight loss beyond lifestyle change at 14.9% for tirzepatide, 10.9% for oral semaglutide, 9.9% for orforglipron and 9.8% for injected semaglutide. The same review found discontinuation for side effects among the highest with orforglipron, stomach and bowel events raised, and fatigue raised (about 100 more people per 1,000 over a year). Injected semaglutide was the only drug in that review linked to fewer deaths from any cause and fewer heart attacks, estimates that came largely from cardiovascular outcome trials in high-risk people.

Keeping the Weight Off: Switching and Stopping

Switching from an injection. ATTAIN-MAINTAIN took people who had already lost weight on injected tirzepatide (205 people) or semaglutide (171 people) and switched them to orforglipron or placebo for 52 weeks. After tirzepatide, people on orforglipron kept an estimated 74.7% of their weight loss against 49.2% on placebo; after semaglutide, 79.3% against 37.6%. Read the other way, the switch did not hold all of the loss, and the trial had no group that stayed on the injections, so it cannot say how the pill compares with simply continuing the injection. The authors also note it lasted only one year.

Stopping altogether. No published orforglipron trial read for this page followed people after they stopped the drug. For the class, the clearest data come from the STEP 1 extension with injected semaglutide: of 327 people who had lost 17.3% of their weight, those who stopped regained 11.6 percentage points within a year, ending 5.6% below their starting weight, and most heart and metabolic improvements drifted back toward where they began. Whether orforglipron behaves the same way has not been measured.

Side Effects in the Trials and on the Label

Stomach and bowel

In the label's pool of the two 72-week weight trials, stomach and bowel reactions affected 60% to 69% of people on the drug and 37% on placebo. Nausea reached 34% to 35% on the two higher doses (10% on placebo), vomiting 21% to 24% (4%), diarrhoea 21% to 25% (11%) and constipation 20% to 27% (9%). They were worse during dose increases and eased over time. About 3% on the drug had severe stomach and bowel reactions, against 1% on placebo. Overall, 8% stopped the drug because of side effects, against 3% on placebo. A 2026 network meta-analysis of the dose-finding trials found a clear dose-response: the 45 mg dose raised the odds of nausea and of vomiting about elevenfold over placebo.

Pancreas

Six adjudicated cases of acute pancreatitis occurred among people on orforglipron (0.14 per 100 patient-years) against one placebo patient with two events (0.04). The label describes the warning signs as persistent or severe abdominal pain, sometimes spreading to the back, with or without vomiting, and directs stopping the drug if pancreatitis is suspected. Pancreatic enzymes rose on average — lipase by 26% to 31% and pancreatic amylase by 16% to 20% — and the label states the meaning of that rise, without other signs, is unknown.

Gallbladder

Gallstones were reported in 1% on orforglipron against 0.7% on placebo, and acute gallbladder inflammation in 0.4% against 0.3%. The label links these events to weight loss.

Other effects listed on the label

• Heart rate rose by 4 to 5 beats per minute on average (0.5 on placebo); a fast heartbeat was reported in 3% against 0.9%.
• Low blood pressure occurred in 2% against 0.5%, and in 4% of those also taking blood-pressure medicines.
• Hair loss was reported in 7% of women and 0.9% of men on the drug; the label ties it to weight loss.
• Low blood sugar (below 54 mg/dL) occurred in 2% of people with diabetes against 0.2%, and in 7% of those also taking a sulfonylurea. In people without diabetes, 0.6% recorded a reading below 54 mg/dL.
• Acute kidney injury was reported in 0.2% against 0.05%, mostly after fluid loss from vomiting or diarrhoea; post-marketing reports with the class include cases needing dialysis.
• Fatigue, burping, reflux, bloating, headache, dizziness, altered taste and skin tingling were also more common than on placebo.

The Thyroid C-Cell Tumour Warning

Orforglipron carries the same boxed warning as the rest of the class, but the label's wording is different and worth reading closely. With the injected drugs, rats and mice develop thyroid C-cell tumours at exposures close to human ones, and these tumours are considered an effect of the glucagon-like peptide-1 receptor in rodents. Orforglipron does not act on the rodent receptor, and in a 2-year rat study and a 26-week study in transgenic mice it caused no tumours. The label states plainly that this does not settle the question: the drug does act on the human receptor, the human relevance of the rodent tumours "has not been determined," and orforglipron "would be expected to have the same on-target class effect" if it worked in rats.

For the class, the label notes post-marketing reports of medullary thyroid carcinoma with liraglutide, with data too limited to establish or exclude a link. It lists the symptoms of thyroid tumours as a lump in the neck, trouble swallowing, shortness of breath and persistent hoarseness, and states that routine calcitonin blood tests or thyroid ultrasound are of uncertain value for early detection. People with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2, are excluded by the contraindication.

Drug Interactions, Contraception and Pregnancy

Because the liver enzyme cytochrome P450 3A4 clears the drug, other medicines can push its levels up or down. On the label, the antibiotic clarithromycin raised orforglipron exposure 3.5-fold and the anti-seizure drug carbamazepine cut it by 82%. The label caps the dose at 9 mg alongside a strong inhibitor of that enzyme, advises against combining it with strong inhibitors that also block the liver transporter OATP1B (ritonavir is the example given), and advises against strong inducers. Orforglipron doubled the level of the active form of simvastatin, and the label caps simvastatin at 20 mg a day alongside it. Insulin and sulfonylurea doses are sometimes lowered at the start to reduce the risk of low blood sugar.

Birth control pills. Because the drug slows stomach emptying, it may change how other pills are absorbed. The label advises people using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for 30 days after starting and for 30 days after each dose increase. Contraceptives not taken by mouth are not expected to be affected.

Pregnancy. The label states that weight loss offers no benefit in pregnancy and may harm the fetus, and that the drug is stopped once a pregnancy is recognised. There are no adequate human studies. In a rabbit dose-finding study, exposure 14 times the human level caused malformations in two fetuses and lower fetal and placental weights; a definitive rabbit study at up to about 6 times the human level found no effects. Safety and effectiveness in children have not been established.

Heart and Liver Findings So Far

Heart. ACHIEVE-4 is the only cardiovascular safety trial published so far. It enrolled 2,749 adults with type 2 diabetes and established heart or kidney disease and compared orforglipron with injected insulin glargine for a median of 2 years. Heart attack, stroke, cardiovascular death or hospital admission for unstable angina occurred in 4.2% on orforglipron and 5.0% on insulin glargine (hazard ratio 0.84, with a confidence interval of 0.59 to 1.20). That met the trial's test of being no worse than insulin, but the interval crosses 1, so it does not show that orforglipron lowers heart events. Deaths were 19 (1.4%) against 43 (3.2%). Stomach and bowel side effects affected 62.1% against 14.2%, while clinically significant low blood sugar was less common on orforglipron (6.8% against 19.2%). The comparison was with another drug, not placebo, and the trial included only people with diabetes.

Liver. A pooled analysis of seven phase 3 trials (11,220 people) found liver enzymes ALT and AST fell on average with orforglipron, and found no case meeting the criteria for drug-induced liver injury; the rate of liver side effects matched the comparison drugs. The analysis was written by the trial sponsor's staff, and its authors call for dedicated studies in fatty liver disease.

What Is Not Yet Known

• Long-term outcomes. The longest published efficacy trials ran 72 weeks; the cardiovascular trial had a median follow-up of 2 years. Effects over many years of use are unknown.
• Cardiovascular benefit. No placebo-controlled outcome trial has reported whether orforglipron reduces heart attacks, strokes or deaths in people with or without diabetes. ACHIEVE-4 tested safety against insulin, not benefit.
• Weight regain after stopping has not been reported for orforglipron itself.
• Head-to-head against the weekly injections for weight loss has not been published.
• Thyroid risk in humans remains undetermined, and rodent studies cannot answer it for this drug.
• Muscle and bone. The label states fat mass fell more than lean mass, but the size of lean-mass loss over years has not been reported in the trials read here.
• Who funded the evidence. Every efficacy trial on this page was funded by the manufacturer, and many authors are its employees. The independent network meta-analyses in the BMJ and in Endocrinology, Diabetes & Metabolism drew on those same trials.

Key Research Papers

1. Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine. 2025;393(18):1796-1806. — PubMed PMID: 40960239
2. Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. New England Journal of Medicine. 2025;393(11):1065-1076. — PubMed PMID: 40544435
3. Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. New England Journal of Medicine. 2023;389(10):877-888. — PubMed PMID: 37351564
4. Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472-483. — PubMed PMID: 37369232
5. Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026;406(10522):2927-2944. — PubMed PMID: 41275875
6. Yokote K, Yamauchi T, Shingaki T, Chin R, Oura T, Nagai Y, et al. Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial. Lancet Diabetes & Endocrinology. 2026 (online ahead of print). — PubMed PMID: 42962687
7. Welch M, Forst T, Jia W, Del Pino PO, Denning M, Wu WS, et al. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. Lancet. 2026;408(10550):125-140. — PubMed PMID: 42259339
8. Rosenstock J, Yabe D, Cox D, Li J, Denning M, Wu WS, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026;407(10534):1147-1160. — PubMed PMID: 41765029
9. Klein KR, Wysham C, Tuttle KR, Davies MJ, Cox D, Chen J, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet. 2026;408(10564):1557-1570. — PubMed PMID: 42815506
10. Giorgino F, D'Souza S, Ludwig L, Kiyosue A, Ibriga H, Rha H, et al. Orforglipron added to titrated insulin glargine in type 2 diabetes: the ACHIEVE-5 randomized clinical trial. JAMA. 2026;336(5):389-399. — PubMed PMID: 42251769
11. Yabe D, Shiraiwa T, Ugai H, Takeuchi M, Suzuki R. Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial. Lancet Diabetes & Endocrinology. 2026;14(10):841-855. — PubMed PMID: 42607698
12. Aronne LJ, Horn DB, le Roux CW, Chao AM, Ho W, Halpern B, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine. 2026;32(7):2679-2687. — PubMed PMID: 42120723
13. Wharton S, Stefanski A, Chen J, Rao G, Twum EA, Denning M. Hepatic safety of orforglipron in adults with obesity or overweight and/or type 2 diabetes: a pooled analysis of the orforglipron phase 3 clinical trials. Diabetes, Obesity and Metabolism. 2026;28(9):8347-8358. — PubMed PMID: 42338042
14. Morse BL, Bhattachar S, Ma X, Coutant DE, Czeskis B, Nicoll C, et al. Disposition and absolute bioavailability of orally administered orforglipron in healthy participants. Clinical Pharmacology in Drug Development. 2026;15(1):e1594. — PubMed PMID: 40888509
15. Hageen AW, Gadelmawla AF, Saleh AO, Abdallfatah A, Mohamed MR, El-Nemr AF, et al. The gastrointestinal safety of orforglipron, a GLP-1 receptor agonist, in adults with or without type 2 diabetes: a network meta-analysis of randomized controlled trials. Endocrinology, Diabetes & Metabolism. 2026;9(3):e70222. — PubMed PMID: 42116665
16. Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026;394:e372161. — PubMed PMID: 42419792
17. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002. — PubMed PMID: 33567185
18. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. — PubMed PMID: 35658024
19. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. — PubMed PMID: 35441470

Label facts on this page come from the U.S. Food and Drug Administration prescribing information for orforglipron tablets (application NDA 220934, label effective 29 July 2026, read through the openFDA drug label database) and the Drugs@FDA approval record. Oral semaglutide administration rules come from that product's prescribing information (NDA 213051).

PubMed Topic Searches

1. PubMed: orforglipron weight-loss trials
2. PubMed: orforglipron in type 2 diabetes
3. PubMed: orforglipron safety
4. PubMed: oral small-molecule glucagon-like peptide-1 receptor agonists

Back to Table of Contents

Connections

• Drugs — the parent section
• Glucagon-Like Peptide-1 Receptor Agonists — semaglutide, tirzepatide and the class
• Weight Loss Studies — the injected drugs' trials
• Side Effects and Cautions — the class safety picture
• Metformin, Berberine and Glucagon-Like Peptide-1 Drugs — the wider drug picture for insulin resistance
• Obesity — the condition the label covers
• Cardio-Renal Protection — heart and kidney outcome trials of the injected drugs
• Glucagon-Like Peptide-1 and Incretins — interactive animation of how the hormone works

Back to Table of Contents

Featured Videos